Leaky lysosomes in lung transplant macrophages: azithromycin prevents oxidative damage

Respiratory Research

Volumn 13, Issue , 2012, Pages

  Persson, H L ^a,b   Vainikka, Linda K ^a   Sege, Maria ^a,b   Wennerström, Urban ^c   Dam Larsen, Sören ^d   Persson, Jenny ^e  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Centre of Surgery and Oncology   (Sweden)

^c Hospital of Västervik   (Sweden)

^d Hospital of Eksjö   (Sweden)

^e RYHOV COUNTY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Bronchiolitis; Ferritin; Fibrosis; Inflammation; Iron; Macrophage

Indexed keywords

AMMONIUM CHLORIDE; AZITHROMYCIN; CYCLOSPORIN A; DEFEROXAMINE; FERRITIN; GLUTATHIONE; IRON; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; OXIDIZING AGENT; TACROLIMUS; ANTIOXIDANT;

ADULT; AGED; ALLOGRAFT; ANIMAL CELL; ARTICLE; BRONCHIOLITIS OBLITERANS; CELL DEATH; CELL LEVEL; CELL PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; LOW DRUG DOSE; LUNG ALVEOLUS MACROPHAGE; LUNG TRANSPLANTATION; LYSOSOME MEMBRANE; MALE; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; OXIDATIVE LYSOSOMAL LEAKAGE; OXIDATIVE LYSOSOMAL MEMBRANE PERMEABILIZATION; OXIDATIVE STRESS; CELL CULTURE; CELL MEMBRANE PERMEABILITY; DRUG EFFECT; LYSOSOME; MACROPHAGE; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PATHOLOGY; PHYSIOLOGY;

ADULT; ANTIOXIDANTS; AZITHROMYCIN; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; FEMALE; HUMANS; IRON; LUNG TRANSPLANTATION; LYSOSOMES; MACROPHAGES; MALE; MIDDLE AGED; OXIDANTS; OXIDATION-REDUCTION;

EID: 84870388806     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-13-83     Document Type: Article

References (51)

1. Olakanmi O, McGowan SE, Hayek MB, Britigan BE. Iron sequestration by macrophages decreases the potential for extracellular hydroxyl radical formation. J Clin Invest 1993, 91:889-899. 10.1172/JCI116310, 288041, 8383703.
2. Mateos F, Brock JH, Pérez-Arellano JL. Iron metabolism in the lower respiratory tract. Thorax 1998, 53:594-600. 10.1136/thx.53.7.594, 1745270, 9797761.
3. Persson HL, Richardson DR. Iron-binding drugs targeted to lysosomes: a potential strategy to treat inflammatory lung disorders. Expert Opin Investig Drugs 2005, 14:997-1008. 10.1517/13543784.14.8.997, 16050792.
4. Persson HL, Vainikka LK. TNF-alpha preserves lysosomal stability in macrophages: a potential defense against oxidative lung injury. Toxicol Lett 2010, 192:261-267. 10.1016/j.toxlet.2009.10.031, 19900513.
5. Persson HL, Vainikka LK, Eriksson I, Wennerström U. TNF-α-stimulated macrophages protect A549 lung cells against iron and oxidation. Exp Toxicol Pathol 2011,
6. Persson HL, Nilsson KJ, Brunk UT. Novel cellular defenses against iron and oxidation: ferritin and autophagocytosis preserve lysosomal stability in airway epithelium. Redox Rep 2001, 6:57-63. 10.1179/135100001101536049, 11333118.
7. Kidane TZ, Sauble E, Linder MC. Release of iron from ferritin requires lysosomal activity. Am J Physiol Cell Physiol 2006, 291:C445-C455. 10.1152/ajpcell.00505.2005, 16611735.
8. Pisoni RL, Acker TL, Lisowski KM, Lemons RM, Thoene JG. A cysteine-specific lysosomal transport system provides a major route for the delivery of thiol to human fibroblast lysosomes: possible role in supporting lysosomal proteolysis. J Cell Biol 1990, 110:327-335. 10.1083/jcb.110.2.327, 2116003, 2404990.
9. Schafer FQ, Buettner GR. Acidic pH amplifies iron-mediated lipid peroxidation in cells. Free Radic Biol Med 2000, 28:1175-1181. 10.1016/S0891-5849(00)00319-1, 10889446.
10. Persson HL. Iron-dependent lysosomal destabilization initiates silica-induced apoptosis in murine macrophages. Toxicol Lett 2005, 159:124-133. 10.1016/j.toxlet.2005.05.002, 15949905.
11. Persson HL, Vainikka LK. Lysosomal iron in pulmonary alveolar proteinosis: a case report. Eur Resp J 2009, 33:673-679.
12. Persson HL, Vainikka LK, Eriksson HB, Wennerström U. Lane-Hamilton syndrome: ferritin protects lung macrophages against iron and oxidation. Chest 2011, 139:361-367. 10.1378/chest.10-0818, 20705801.
13. Brunk UT, Neuzil J, Eaton JW. Lysosomal involvement in apoptosis. Redox Rep 2001, 6:91-97. 10.1179/135100001101536094, 11450988.
14. Persson HL. Radiation-induced lysosomal iron reactivity: implications for radioprotective therapy. IUBMB Life 2006, 58:395-401. 10.1080/15216540600755998, 16801214.
15. Wang L, Antonini JM, Rojanasakul Y, Castranova Y, Scabilloni JF, Mercer RR. Potential role of apoptotic macrophages in pulmonary inflammation and fibrosis. J Cell Physiol 2003, 194:215-224. 10.1002/jcp.10220, 12494460.
16. Hodge S, Hodge K, Scicchitano R, Reynolds PN, Holmes M. Alveolar macrophages from subjects with chronic obstructive pulmonary disease are deficient in their ability to phagocytose apoptotic airway epithelial cells. Immunol Cell Biol 2003, 81:289-296. 10.1046/j.1440-1711.2003.t01-1-01170.x, 12848850.
17. Drakopanagiotakis F, Xifteri A, Polychronopoulos V, Bouros D. Apoptosis in lung injury and fibrosis. Eur Respir J 2008, 32:1631-1638. 10.1183/09031936.00176807, 19043009.
18. Krysko O, Vandenabeele P, Krysko DV, Bachert C. Impairment of phagocytosis of apoptotic cells and its role in chronic airway diseases. Apoptosis 2010, 15:1137-1146. 10.1007/s10495-010-0504-x, 20449769.
19. Mukaro VR, Hodge S. Airway clearance of apoptotic cells in COPD. Curr Drugs Target 2011, 12:460-468.
20. Todd JL, Palmer SM. Bronchiolitis obliterans syndrome: the final frontier for lung transplantation. Chest 2011, 140:502-508. 10.1378/chest.10-2838, 21813529.
21. Vos R, Vanaudenaerde BM, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, Van Raemdonck DE, Schoonis A, Nawrot TS, Dupont LJ, Verleden GM. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 2011, 37:164-172. 10.1183/09031936.00068310, 20562124.
22. Crosbie PA, Woodhead MA. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009, 33:171-181. 10.1183/09031936.00042208, 19118228.
23. Friedlander AL, Albert RK. Chronic macrolide therapy in inflammatory airways diseases. Chest 2010, 138:1202-1212. 10.1378/chest.10-0196, 21051396.
24. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanisms of delivery and release at site of infection. Antimicrob Agents Chemother 1989, 33:277-282. 10.1128/AAC.33.3.277, 171479, 2543276.
25. Laufen H, Wildfeuer A, Lach P. Mechanism of azithromycin uptake in human polymorphonuclear leucocytes. Arzneim.-Forsch Drug Res 1990, 40:686-689.
26. Carlier MB, Garcia-Luque I, Montenez JP, Tulkens PM, Piret J. Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture. Int J Tissue React 1994, 16:211-220.
27. Persson HL, Yu Z, Tirosh O, Eaton JW, Brunk UT. Prevention of oxidant-induced cell death by lysosomotropic iron chelators. Free Radic Biol Med 2003, 34:1295-1305. 10.1016/S0891-5849(03)00106-0, 12726917.
28. Yu Z, Eaton JW, Persson HL. The radioprotective agent, amifostine, suppresses the reactivity of intralysosomal iron. Redox Rep 2003, 8:341-355. 10.1179/135100003225003375, 14980066.
29. Yu Z, Persson HL, Eaton JW, Brunk UT. Intralysosomal iron: a major determinant of oxidant-induced cell death. Free Radic Biol Med 2003, 34:1243-1252. 10.1016/S0891-5849(03)00109-6, 12726912.
30. Persson HL, Kurz T, Eaton JW, Brunk UT. Radiation-induced cell death: Importance of lysosomal destabilization. Biochem J 2005, 389:877-884. 10.1042/BJ20050271, 1180739, 15813701.
31. Ohkuma S, Poole B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci USA 1978, 75:3327-3331. 10.1073/pnas.75.7.3327, 392768, 28524.
32. Golde DW, Drew WL, Klein HZ, Finley TN, Cline MJ. Occult pulmonary haemorrhage in leukemia. Br Med J 1975, 2:166-168. 10.1136/bmj.2.5964.166, 1675967, 1125726.
33. Jäättelä M, Tschopp J. Caspase-independent cell death in T lymphocytes. Nat Immunol 2003, 4:416-423. 10.1038/ni0503-416, 12719731.
34. Danel C, Israel-Biet D, Costabel U, Rossi GA, Wallaert B. The clinical role of BALF in rare pulmonary diseases. Eur Resp Rev 1991, 2:83-88.
35. Arosio P, Levi S. Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochim Biophys Acta 2010, 1800:783-792. 10.1016/j.bbagen.2010.02.005, 20176086.
36. Wolters PJ, Chapman HA. Importance of lysosomal cysteine proteases in lung disease. Resp Res 2000, 1:170-177.
37. Mattson JP, Väänänen K, Wallmark B, Lorentzon P. Omeprazole and bafilomycin, two proton inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim Biophys Acta 1991, 1065:261-268. 10.1016/0005-2736(91)90238-4, 1647821.
38. Suzuki M, Mori M, Miura S, Suematsu M, Fukumura D, Kimura H, Ishii H. Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radic Biol Med 1996, 21:727-731. 10.1016/0891-5849(96)00180-3, 8891677.
39. Grinpukel S, Sewell R, Yeomans N, Mihaly G, Smallwood R. Lack of effect of omeprazole, a potent inhibitor of gastric (H+ + K+) ATPase, on hepatic lysosomal integrity and enzyme activity. J Pharm Pharmacol 1986, 38:158-160.
40. Fujisaki H, Oketani K, Nagakawa J, Takenaka O, Yamanishi Y. Effects of rabeprazole, a gastric proton pump inhibitor, on biliary and hepatic lysosomal enzymes in rats. Jpn J Pharmacol 1998, 76:279-288. 10.1254/jjp.76.279, 9593221.
41. Udelnow A, Kreyes A, Ellinger S, Landfester K, Walther P, Klapperstueck T, Wohlrab J, Henne-Bruns D, Knippschild U, Würl P. Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells. PLoS One 2011, 6:e20143. 10.1371/journal.pone.0020143, 3101238, 21629657.
42. Van Bambeke F, Montenez JP, Piret J, Tulkens PM, Courtoy PJ, Mingeot-Leclercq MP. Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity. Eur J Pharmacol 1996, 314:203-214. 10.1016/S0014-2999(96)00552-3, 8957238.
43. Van Bambeke F, Gerbaux C, Michot JM, D'Yvoire MB, Montenez JP, Tulkens PM. Lysosomal alterations induced in cultured rat fibroblasts by long-term exposure to low concentrations of azithromycin. J Antimicrob Chemother 1998, 42:761-767. 10.1093/jac/42.6.761, 10052900.
44. Appelqvist H, Nilsson C, Garner B, Brown AJ, Kågedal K, Ollinger K. Attenuation of the lysosomal death pathway by lysosomal cholesterol accumulation. Am J Pathol 2011, 178:629-639. 10.1016/j.ajpath.2010.10.030, 3069902, 21281795.
45. Reiners JJ, Kleinman M, Kessel D, Mathieu PA, Caruso JA. Nonesterified cholesterol content of lysosomes modulates susceptibility to oxidant-induced permeabilization. Free Radic Biol Med 2011, 50:281-294. 10.1016/j.freeradbiomed.2010.11.006, 3018561, 21074609.
46. Lode H, Borner K, Koeppe P, Schaberg T. Azithromycin - review of key chemical, pharmacokinetic and microbiological features. J Antimicrobial Chemotherapy 1996, 37:1-8.
47. Tyteca D, Van Der Smissen P, Mettlen M, Van Bambeke F, Tulkens PM, Mingeot-Leclercq MP, Courtoy PJ. Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages. Exp Cell Res 2002, 281:86-100. 10.1006/excr.2002.5613, 12441132.
48. El-Rjoob A-W, Al-Mustafa J, Taha Z, Abous M. Spectroscopic and conductometric investigation of the interaction of azithromycin with iron (II) ion. Jordan J Chem 2008, 3:199-209.
49. Baz MA, Ghio AJ, Roggli VL, Tapson VF, Piantadosi CA. Iron accumulation in lung allografts after transplantation. Chest 1997, 112:435-439. 10.1378/chest.112.2.435, 9266881.
50. Sandmeier P, Speich R, Grebski E, Vogt P, Russi EW, Weder W, Boehler A. Iron accumulation in lung allografts is associated with acute rejection but not with adverse outcome. Chest 2005, 128:1379-1384. 10.1378/chest.128.3.1379, 16162732.
51. Pugh C, Hathwar V, Richards JH, Stonehuerner J, Ghio AJ. Disruption of iron homeostasis in the lungs of transplant patients. J Heart Lung Transplant 2005, 24:1821-1827. 10.1016/j.healun.2005.03.016, 16297788.